Additionally, fusion gene-dependent BCL2 overexpression and its contribution to tumorigenesis have been reported, and BCL2-related anti-apoptotic pathways are also considered a potential therapeutic target for SS [12,36,37,38]. This evidence concerns the gene BCL2 and synovial sarcoma.